Quince Therapeutics Amends 8-K to Clarify Positive LAM-001 Phase 2a Efficacy Data

summarizeSummary

Quince Therapeutics filed an amended 8-K to correct and clarify positive Phase 2a clinical trial results for its newly acquired drug, LAM-001, confirming significant reductions in pulmonary vascular resistance.

check_boxKey Events

• Material Data Correction

  The company amended its May 18, 2026 8-K to correct the reported percentage changes in Pulmonary Vascular Resistance (PVR) for LAM-001 Phase 2a data.

• Clarification of Positive Efficacy

  The correction changes "35.3%" and "28.1%" to "-35.3%" and "-28.1%", respectively, confirming that LAM-001 achieved significant PVR reductions, a positive clinical outcome for pulmonary hypertension.

• Reinforces Drug Pipeline Value

  This clarification reinforces the positive efficacy of LAM-001, a key asset acquired through Orphai Therapeutics, which is important for the company's pipeline given recent challenges.

auto_awesomeAnalysis

This amendment clarifies previously reported Phase 2a clinical trial data for LAM-001, a drug acquired through Orphai Therapeutics. The correction changes positive percentage changes in Pulmonary Vascular Resistance (PVR) to negative, confirming that the drug achieved significant PVR reductions. This is a crucial clarification, as PVR reduction indicates positive efficacy in treating pulmonary hypertension, reinforcing the drug's potential and the value of the recent acquisition.